Home/Pipeline/NBP-14

NBP-14

Alzheimer's Disease

Pre-clinicalActive

Key Facts

Indication

Alzheimer's Disease

Phase

Pre-clinical

Status

Active

Company

Neuro Bio

About Neuro Bio

Neuro Bio is a private, preclinical-stage biotech pioneering a disruptive hypothesis for Alzheimer's disease (AD) that challenges the dominant amyloid dogma. The company's core discovery is the T14 peptide, which it posits triggers an aberrant, developmental-like process in specific vulnerable neurons, driving neurodegeneration upstream of amyloid plaque formation. This mechanism informs a dual strategy: a diagnostic pipeline for early detection of T14 in nasal secretions and saliva, and a therapeutic pipeline led by NBP-14, an antagonist of T14. The company is also exploring applications of its platform in oncology, dermatology, and diabetic retinopathy, indicating a broader platform potential.

View full company profile

Therapeutic Areas

Alzheimer's Disease Neurodegenerative Diseases Oncology Dermatology Ophthalmology

Other Alzheimer's Disease Drugs

Drug	Company	Phase	Status
NUZ-001	Neurizon Therapeutics	Preclinical	Active
ALZN002	Alzamend Neuro	Preclinical	Research
P021	Phanes Biotech	Preclinical	Active
PB43D	Phanes Biotech	Preclinical	Active
UB-311	Vaxxinity	Phase 2	Active
Lecanemab	BioArctic	Launched	Active (Commercial)
BAN2401	BioArctic	Preclinical	Active
Undisclosed Programs	johnson-and-johnson-innovative-medicine	Pipeline	Active
MK-6240 (florquinitau)	Lantheus Medical Imaging	Regulatory Filing	Filed
NAV-4694 (flutafuranol)	Lantheus Medical Imaging	Phase 3	Active
LNTH-2620/PI-2620	Lantheus Medical Imaging	Phase 3	Recruiting
itMSCs	Stemedica Cell Technologies	Clinical Development	Active